Search Results
Search for other papers by Maria Denaro in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Anello Marcello Poma in
Google Scholar
PubMed
Search for other papers by Nicla Borrelli in
Google Scholar
PubMed
Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Massimo Chiarugi in
Google Scholar
PubMed
Search for other papers by Paolo Miccoli in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
-pathological features such as age, sex, tumor size and aggressive behavior ( Yip et al. 2011 , Wang et al. 2013 ). Some studies have evaluated the association between genetic alterations and miRNA expression in papillary thyroid carcinomas (PTCs), but the results
Search for other papers by E Fiore in
Google Scholar
PubMed
Search for other papers by T Rago in
Google Scholar
PubMed
Search for other papers by F Latrofa in
Google Scholar
PubMed
Search for other papers by M A Provenzale in
Google Scholar
PubMed
Search for other papers by P Piaggi in
Google Scholar
PubMed
Search for other papers by A Delitala in
Google Scholar
PubMed
Search for other papers by M Scutari in
Google Scholar
PubMed
Search for other papers by F Basolo in
Google Scholar
PubMed
Search for other papers by G Di Coscio in
Google Scholar
PubMed
Search for other papers by L Grasso in
Google Scholar
PubMed
Search for other papers by A Pinchera in
Google Scholar
PubMed
Search for other papers by P Vitti in
Google Scholar
PubMed
probability that mutated oncogenes may cause cancer clinically detectable. PTC frequently has genetic alterations leading to the activation of the mitogen-activated protein kinase signaling pathway. Most common mutations in PTC are point mutations of the BRAF
Search for other papers by Toyoshi Endo in
Google Scholar
PubMed
Search for other papers by Tetsuro Kobayashi in
Google Scholar
PubMed
-stimulating hormone (TSH; Nikiforov & Nikiforova 2011 ). The RET/PTC rearrangement and the BRAF V600E point mutation are the two most common genetic alterations associated with PTCs; the prevalence of RET/PTC varies from 2.5 to 78% ( Zou et al . 1994
Search for other papers by Esther Korpershoek in
Google Scholar
PubMed
Departments of Pathology, Neurology, Department of Paediatric Oncology and Haematology, Josephine Nefkens Institute, Erasmus Medical Centre, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Search for other papers by Nanne K Kloosterhof in
Google Scholar
PubMed
Search for other papers by Angelique Ziel-van der Made in
Google Scholar
PubMed
Search for other papers by Hanneke Korsten in
Google Scholar
PubMed
Search for other papers by Lindsey Oudijk in
Google Scholar
PubMed
Search for other papers by Jan Trapman in
Google Scholar
PubMed
Search for other papers by Winand N M Dinjens in
Google Scholar
PubMed
Search for other papers by Ronald R de Krijger in
Google Scholar
PubMed
appeared to be no difference in frequencies between benign or malignant tumours ( Petri et al . 2008 ). Genetic alterations have been investigated by CGH in two Pten KO mouse models ( You et al . 2002 , Korpershoek et al . 2009 ). The first study
Search for other papers by Wenzel M Hackeng in
Google Scholar
PubMed
Search for other papers by Lodewijk A A Brosens in
Google Scholar
PubMed
Department of Endocrinology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands
Search for other papers by Koen M A Dreijerink in
Google Scholar
PubMed
vs aggressive insulinomas The low incidence of aggressive insulinomas has resulted in few data on genetic alterations in these tumors. The first evidence of biological differences between indolent and aggressive insulinomas was discovered by
Search for other papers by Devora Champa in
Google Scholar
PubMed
Search for other papers by Marika A Russo in
Google Scholar
PubMed
Search for other papers by Xiao-Hui Liao in
Google Scholar
PubMed
Department of Developmental and Molecular Biology, Departments of Medicine, Pediatrics and Committee on Genetics, Department of Pathology, Albert Einstein College of Medicine, Price Center for Genetic and Translational Medicine, 1301 Morris Park Avenue, Room 302, Bronx, New York 10461, USA
Search for other papers by Samuel Refetoff in
Google Scholar
PubMed
Search for other papers by Ronald A Ghossein in
Google Scholar
PubMed
Search for other papers by Antonio Di Cristofano in
Google Scholar
PubMed
of whether these tumors are sensitive to the inhibition of MEK1 and MEK2. We used two cell lines derived from our mouse model, as well as a human ATC cell line, Cal62, which harbors the same genetic alterations and thus represents an appropriate human
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands
Search for other papers by Elizabeth J de Koster in
Google Scholar
PubMed
Search for other papers by Willem E Corver in
Google Scholar
PubMed
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands
Biomedical Photonic Imaging Group, University of Twente, Enschede, the Netherlands
Search for other papers by Lioe-Fee de Geus-Oei in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands
Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy
Search for other papers by Wim J G Oyen in
Google Scholar
PubMed
Search for other papers by Dina Ruano in
Google Scholar
PubMed
Search for other papers by Abbey Schepers in
Google Scholar
PubMed
Search for other papers by Marieke Snel in
Google Scholar
PubMed
Search for other papers by Tom van Wezel in
Google Scholar
PubMed
Search for other papers by Dennis Vriens in
Google Scholar
PubMed
Search for other papers by Hans Morreau in
Google Scholar
PubMed
clearly distinguished from true OCN, as it is different in both origin and genetic alterations. It may occur in lymphocytic thyroiditis, oncocytic variant papillary thyroid carcinoma, medullary thyroid carcinoma, parathyroid lesions, and non
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
network behavior in the context of specific genetic alterations can have an influence on therapy. Since 2005, I am involved in the activities of the ENETS, where I participate in consensus meetings for the construction of guidelines for diagnosis and
Search for other papers by M Montani in
Google Scholar
PubMed
Search for other papers by A M Schmitt in
Google Scholar
PubMed
Search for other papers by S Schmid in
Google Scholar
PubMed
Search for other papers by T Locher in
Google Scholar
PubMed
Search for other papers by P Saremaslani in
Google Scholar
PubMed
Search for other papers by P U Heitz in
Google Scholar
PubMed
Search for other papers by P Komminoth in
Google Scholar
PubMed
Search for other papers by A Perren in
Google Scholar
PubMed
carcinoma. Journal of Molecular Medicine 81 819 –823. Khosla S , Patel VM, Hay ID, Schaid DJ, Grant CS, van Heerden JA & Thibodeau SN 1991 Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas
Search for other papers by B Kwabi-Addo in
Google Scholar
PubMed
Search for other papers by M Ozen in
Google Scholar
PubMed
Search for other papers by M Ittmann in
Google Scholar
PubMed
other genetic alterations. A major goal is to understand the underlying differences in signal transduction between FGFR-1 and FGFR-2 that could lead to enhancement or inhibition of tumor progression by these two related receptors. In this regard